Eli Lilly Enters the Obesity Battle: New Pill Poised to Challenge Novo Nordisk’s Oral Wegovy, Shaking Up the Weight Loss Market and Investor Landscape
Eli Lilly’s Obesity Pill: Underwhelming Trial Data but a Potential Game-Changer in the Weight Loss Market Eli Lilly’s recent trial results for its obesity pill, orforglipron, sent its stock tumbling 13% initially, reflecting Wall Street’s disappointment over the drug’s lower-than-expected weight loss efficacy and higher side effects. Yet, the shares have rebounded about 12% since,…
